F024 Pemphigus and Pemphigoid: Evidence-based Updates
DESCRIPTION
In this session we will review real-world pearls for the diagnosis and treatment of pemphigus and pemphigoid with the goal of providing tips that are easy to implement into clinical practice. We will discuss new information regarding mechanisms of disease pathogenesis and how these mechanisms provide rationale for new therapies. We will review the efficacy and safety of both established and newer treatments based on current evidence. Finally, we will present challenging cases that provide important teaching points. At the end of this session the audience will be able to diagnose and treat pemphigus and pemphigoid patients more effectively and confidently.
LEARNING OBJECTIVES
Describe relevant pathogenic mechanisms of pemphigus and pemphigoid.
Diagnose pemphigus and pemphigoid more effectively.
Develop treatment plans for pemphigus and pemphigoid with more confidence.
SCHEDULE
1:00 PM
Pemphigus: Evidence based updates and practical clinical pearls
Donna Culton, MD, PhD, FAAD
1:25 PM
Bullous (and nonbullous) pemphigoid: Evidence based updates and practical clinical pearls
Annette Czernik, MD, FAAD
1:50 PM
Your new secret weapon: The IPPF
Rebecca Strong, RN
2:05 PM
Challenging cases and lessons learned
Heather M Holahan, MD, FAAD
2:20 PM
Mucous membrane pemphigoid: Evidence based updates and practical clinical pearls
Brittney Schultz, MD, FAAD
2:45 PM
Q&A
DIRECTOR
Donna Culton, MD, PhD, FAAD
SPEAKERS
Annette Czernik, MD, FAAD
Heather M Holahan, MD, FAAD
Brittney Schultz, MD, FAAD
Rebecca Strong, RN
HANDOUTS
DISCLOSURES
Donna Culton, MD, PhD, FAAD
AbbVie – Advisory Board(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Almirall – Consultant (1099 relationship)(Fees); arGEN-X – Consultant(Fees); Eli Lilly and Company – Investigator(Salary); Enveda Biosciences – Consultant (1099 relationship)(Fees); Glycoera – Advisory Board(Fees); Incyte Corporation – Investigator(Salary); Janssen Global Services, LLC – Other(Residency/Fellowship Program Funding); Leo Pharma – Consultant (1099 relationship)(Fees), Investigator(Salary); Novartis – Advisory Board(Fees); Organon – Investigator(Salary); Pfizer Inc. – Investigator(Salary); Priovant Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Salary); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Salary), Speaker(Fees); Sanofi – Investigator(Salary); Sanofi Genzyme – Consultant (1099 relationship)(Fees); UpToDate – Other(Honoraria);
Annette Czernik, MD, FAAD
argenx – Consultant (1099 relationship)(Honoraria); Regeneron Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria);
Heather M Holahan, MD, FAAD
Novartis – Independent Contractor(Fees);
Brittney Schultz, MD, FAAD
Biocryst – Advisory Board(Honoraria); Hoffman-La Roche Ltd. – Investigator(No Compensation Received); Sanofi/Regeneron – Advisory Board(Honoraria); UCB – Investigator(No Compensation Received);
Rebecca Strong, RN
International Pemphigus and Pemphigoid Foundation – Employee(Salary);